Disease · MONDO_0016696
anaplastic oligodendroglioma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. anaplastic oligodendroglioma. Diseases, record MONDO_0016696. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016696
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
WHO grade III oligodendroglial neoplasm, WHO grade III oligodendroglial tumor, WHO grade III oligodendroglial tumour, malignant oligodendroglioma, oligodendroglioma, anaplastic, malignant, oligodendroglioma, malignant, undifferentiated oligodendroglioma
- Open Targets
Drugs30
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| PROCARBAZINE | CHEMBL1321 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 2 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| BUSULFAN | CHEMBL820 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| THIOTEPA | CHEMBL671 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| 6-O-BENZYLGUANINE | CHEMBL407874 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETIRINOTECAN PEGOL | CHEMBL3039558 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 30
See all 30 drugsTargets51
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 51
See all 51 targetsTrials26
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00588523 | Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma | Phase 2 | 60 | 2023-10-27 | CNS Cancer, CNS BRAIN | BUSULFAN, TEMOZOLOMIDE, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
| NCT00859222 | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Phase 1/2 | 51 | 2016-11-28 | Malignant Glioma | BEVACIZUMAB, PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | Phase 2 | 20 | 2015-06-11 | Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas, Glioblastomas (GBM) | ETIRINOTECAN PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT01721577 | Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | Phase 1/2 | 10 | 2023-05-22 | Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Anaplastic Ependymoma | AXL-1717 | Its record names the disease | ClinicalTrials.gov |
| NCT00047879 | Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas | Phase 2 | 7 | 2011-10-26 | Glioma | INTERFERON ALFA-2B, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00002840 | Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma | Phase 3 | 350 | Brain and Central Nervous System Tumors | LOMUSTINE, PROCARBAZINE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00002569 | Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma | Phase 3 | 299 | Brain and Central Nervous System Tumors | LOMUSTINE, PROCARBAZINE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00039364 | Imatinib Mesylate in Treating Patients With Gliomas | Phase 2 | 112 | Brain and Central Nervous System Tumors | IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01534845 | Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion | Phase 2 | 90 | Anaplastic Glioma of Brain, Loss of Chromosomes 1p/19q | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00613093 | Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma | Phase 2 | 67 | Glioblastoma Multiforme, Anaplastic Glioma | 6-O-BENZYLGUANINE, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 26
See all 26 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| AXL1717, 400mg Initial Dose vs AXL1717, 300mg Initial Dose: Phase I Subjects - Imaging Evidence of Response. | 0 of 2 | 5 of 7 | 9 | NCT01721577 | Trial comparisons |
| Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: The Number of Participants With Adverse Events | 4 of 4 | 2 of 3 | 7 | NCT00047879 | Trial comparisons |
| Glioblastoma Multiforme Stratum vs Anaplastic Glioma Stratum: serious adverse events | 3 of 4 | 2 of 3 | 7 | NCT00047879 | Trial comparisons |
Papers from its trials28
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016696
GET https://conductscience.org/api/diseases/v1/MONDO_0016696/drugs?page=2